Ketoconazole Tablets Rx
Generic Name and Formulations:
Various generic manufacturers
Indications for Ketoconazole Tablets:
Susceptible systemic fungal infections (blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, paracoccidioidomycosis) in those who have failed or are intolerant to other therapies. Do not use for fungal meningitis.
Initially 200mg daily; max 400mg daily. Usual duration: 6 months.
<2yrs: not studied. >2yrs: see full labeling.
Concomitant dofetilide, quinidine, pimozide, cisapride, methadone, disopyramide, dronedarone, ranolazine, felodipine, nisoldipine, tolvaptan, irinotecan, lurasidone, alprazolam, oral midazolam, oral triazolam, eplerenone, ergot alkaloids, simvastatin, lovastatin, colchicine. Acute or chronic liver disease.
Should be used only when other effective antifungal therapy is not available or tolerated. Risk of serious hepatotoxicity; monitor closely. Obtain SGGT, ALT/AST, bilirubin, alkaline phosphatase, PT, INR, viral hepatitides at baseline. Monitor ALT weekly during therapy; if ALT is >30% baseline or symptoms develop, interrupt and perform full liver function tests. QT prolongation. Monitor adrenal function in adrenal insufficiency, borderline adrenal function, or under prolonged stress. Children. Pregnancy (Cat.C). Nursing mothers: not recommended.
See Contraindications. QT prolongation with concomitant dofetilide, quinidine, pimozide, cisapride, methadone, disopyramide, dronedarone, ranolazine. Concomitant sirolimus, everolimus, temsirolimus, tamsulosin, rifabutin, rivaroxaban, salmeterol, dasatinib, lapatinib, nilotinib: not recommended. Potentiates alfentanil, sufentanil, fentanyl, buprenophine, oxycodone, calcium channel blockers, bosentan, buspirone, carbamazepine, cilostazol, cyclosporine, digoxin, oral anticoagulants, indinavir, saquinavir, sildenafil, vardenafil, tadalafil, tacrolimus, telithromycin, atorvastatin, tolterodine, trimetrexate, verapamil, vinca alkaloids, bortezomib, busulphan, docetaxel, erlotinib, imatinib, ixabepilone, paclitaxel, aripiprazole, quetiapine, ramelteon, risperidone; monitor and adjust doses. Avoid alcohol or other hepatotoxic drugs. Antagonized by carbamazepine, efavirenz, nevirapine, phenytoin, rifabutin, isoniazid, rifampicin: not recommended. Potentiated by CYP3A4 inhibitors (eg, ritonavir, ritonavir/darunavir, ritonavir/fosamprenavir); adjust ketoconazole dose as needed. Separate dosing of acid neutralizing drugs (eg, aluminum hydroxide) by at least 1hr before or 2hrs after ketoconazole; should give with acidic beverage (eg, non-diet cola). Caution with concomitant repaglinide, saxagliptin, praziquantel, maraviroc, H2-blockers, PPIs, and eletriptan (do not use within 72hrs of ketoconazole). Monitor digoxin, phenytoin, carbamazepine, oral anticoagulants. Consider reducing concomitant dabigatran dose in moderate renal impairment.
Nausea, vomiting, abdominal pain, urticaria, pruritus, insomnia, nervousness, CNS disorders, photophobia, orthostatic hypotension, myalgia, menstrual disorder, asthenia, fatigue, hot flush, malaise, edema peripheral, pyrexia, chills; hepatotoxicity, anaphylaxis, decreased testosterone levels, Torsades de pointes (may be fatal).
Formerly known under the brand name Nizoral.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|